Johan Spetz

Profiling proteomic responses in small intestinal neuroendocrine tumor GOT1 after [177Lu]Lu-DOTATATE therapy

Abstract Background Peptide receptor radionuclide therapy with [ 177 Lu]Lu-DOTATATE is an established treatment for somatostatin receptor–expressing neuroendocrine tumors. Although strong anti-tumor effects have been demonstrated in experimental models, curative responses in pati...